Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 27 for:    bladder art
Previous Study | Return to List | Next Study

Adjuvant Radiotherapy in Patients With Pathological High-risk Bladder Cancer (GETUG-AFU 30) (Bladder-ART)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03333356
Recruitment Status : Recruiting
First Posted : November 6, 2017
Last Update Posted : September 28, 2021
Sponsor:
Information provided by (Responsible Party):
UNICANCER

Brief Summary:

This is a randomized multicentre study in patients with high-risk MIBC to investigate adjuvant radiotherapy after radical cystectomy and pelvic lymph node dissection.

The objective of the study is to provide evidence that adjuvant radiotherapy improves loco-regional control with potential benefits in survival. The study will also evaluate the quality of life of patients and the tolerance of the treatment.


Condition or disease Intervention/treatment Phase
Patients With High-risk MIBC Radiation: pelvic radiotherapy Not Applicable

Detailed Description:

INDICATION:

Patients with pathological high-risk muscle invasive bladder cancer treated by radical cystectomy and pelvic lymph nodes dissection

METHODOLOGY:

Multicenter randomised phase II study in high-risk bladder cancer patients treated by radical cystectomy with pelvic lymph nodes dissection assessing :

  • Experimental Arm: adjuvant pelvic radiotherapy consisting of 28 x 1.8 Gy fractions (total dose of 50.4 Gy), 5 days per week, 1 fraction /day (duration of RT is 38 days).
  • Standard Arm: surveillance. Eligible patients will be randomised, in a 3:1 ratio, to receive either: adjuvant pelvic radiotherapy (Experimental Arm), or surveillance (Standard Arm).

PRIMARY OBJECTIVE:

The primary objective of the trial is to assess the efficacy of adjuvant radiotherapy in patients with high-risk bladder cancer after radical cystectomy and pelvic lymph nodes dissection. Efficacy will be assessed in terms of pelvic recurrence-free survival (PRFS) at 3 years.

SECONDARY OBJECTIVES:

For each treatment arm (adjuvant pelvic radiotherapy [Experimental Arm], or surveillance [Standard Arm]), these objectives will be evaluated independently.

  • To evaluate 5-year pelvic recurrence-free survival (PRFS)
  • To evaluate disease-free survival (DFS) at 3 and 5 years.
  • To evaluate overall survival (OS) at 3 and 5 years.
  • To evaluate metastasis-free survival (MFS) at 3 and 5 years.
  • To evaluate disease-specific survival (DSS) at 3 and 5 years.
  • To evaluate the tolerance and safety of each treatment strategy.
  • To evaluate patients' quality of life.

Ancillary studies Objectives:

  • Investigation of individual predisposition to develop radiotherapy induced late digestive toxicity using the radiation-induced lymphocyte apoptosis (RILA) assay
  • The analyse of genomic and transcriptome correlation between different clusters and oncological outcomes
  • Dosimetric banking to evaluate the correlation of Dose-Volume Histogram with:
  • Gastrointestinal toxicity grade ≥2;
  • Pelvic recurrence (radiotherapy volumes, mapping of recurrences).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 109 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Adjuvant Radiotherapy in Patients With Pathological High-risk Bladder Cancer: A Randomized Multicentre Phase II Study
Actual Study Start Date : April 19, 2018
Estimated Primary Completion Date : December 2027
Estimated Study Completion Date : December 2027

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bladder Cancer

Arm Intervention/treatment
Experimental: Experimental Arm
adjuvant pelvic radiotherapy consisting of 28 x 1.8 Gy fractions (total dose of 50.4 Gy), 5 days per week, 1 fraction / day (duration of RT is 38 days).
Radiation: pelvic radiotherapy
adjuvant pelvic radiotherapy consisting of 28 x 1.8 Gy fractions (total dose of 50.4 Gy), 5 days per week, 1 fraction / day (duration of RT is 38 days).

No Intervention: Standard Arm
Surveillance



Primary Outcome Measures :
  1. pelvic recurrence-free survival (PRFS) [ Time Frame: 3 years ]
    The PRFS is defined as the delay between randomization and pelvic recurrence or death, whichever occurs first. The pelvic recurrence will be evaluated according to RECIST V1.1 criteria.


Secondary Outcome Measures :
  1. pelvic recurrence-free survival (PRFS) [ Time Frame: 5 years ]
    The PRFS is defined as the delay between randomization and pelvic recurrence or death, whichever occurs first. The pelvic recurrence will be evaluated according to RECIST V1.1 criteria.

  2. Disease-free survival (DFS) [ Time Frame: 3 years ]
    DFS is defined as the delay between randomization and tumor progression (local, regional, or distant) or death of any cause, whichever occurs first.

  3. Disease-free survival (DFS) [ Time Frame: 5 years ]
    DFS is defined as the delay between randomization and tumor progression (local, regional, or distant) or death of any cause, whichever occurs first.

  4. Overall Survival (OS) [ Time Frame: 3 years ]
    OS is defined as the delay between randomization and death, of any cause.

  5. Overall Survival (OS) [ Time Frame: 5 years ]
    OS is defined as the delay between randomization and death, of any cause.

  6. Metastasis-free survival (MFS) [ Time Frame: 3 years ]
    MFS is defined as the delay between randomization, and metastasis (clinical or radiological) or death of any cause whichever occurs first.

  7. Metastasis-free survival (MFS) [ Time Frame: 5 years ]
    MFS is defined as the delay between randomization, and metastasis (clinical or radiological) or death of any cause whichever occurs first.

  8. Disease-specific survival (DSS) [ Time Frame: 3 years ]
    DSS is defined as the delay between randomization and death due to bladder cancer.

  9. Disease-specific survival (DSS) [ Time Frame: 5 years ]
    DSS is defined as the delay between randomization and death due to bladder cancer.

  10. Tolerance will be evaluated by toxicity: acute (<6 months after RT) and late (≥6 months after RT), assessed using the NCI CTCAE Version N°4.0 [ Time Frame: 5 years ]
    The tolerance will be evaluated by toxicity: acute (<6 months after RT) and late (≥6 months after RT), assessed using the NCI CTCAE Version N°4.0.

  11. Patients' quality of Life [ Time Frame: 5 years ]
    EORTC QLQ-C30

  12. Patient quality of Life [ Time Frame: 5 years ]
    The Bladder Cancer Index (BCI)

  13. Evaluation of acute and late toxicities [ Time Frame: 5 years ]
    The safety will be evaluated by toxicity: acute (<6 months after RT) and late (≥6 months after RT), assessed using the NCI CTCAE Version N°4.0.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

To be eligible, the patients must fulfil all of the following inclusion criteria:

  1. Patients with histologically-confirmed muscle-invasive bladder cancer, either with pure urothelial carcinomas, or dominant urothelial carcinomas (>50%) combined with other histological variants including: micropapillary, epidermoid, or adenocarcinomas, are eligible. Patients with small cell variants, pure adenocarcinomas, or pure epidermoid carcinomas are not eligible.
  2. Patients with radical cystectomy and pelvic lymph nodes dissection with no microscopic residual disease (R0 and R1).

    Note that only R1 patients without urinary diversion as orthotropic neo-bladder replacement are eligible for the study, to limit cystectomy bed radiation induced toxicities.

  3. Patients with tumours of TNM staging: pN0-2, M0 by imagery, and pT3a, pT3b, pT4a, and pT4b, as well as, pTX-pN1-2, pTX-NX-R1 are eligible.
  4. Patients having received neo-adjuvant or adjuvant chemotherapy treatment are eligible. Randomization is allowed only if AE due to chemotherapy are ≤grade 2 at randomization.
  5. Patients ≥18 years old.
  6. Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
  7. Absolute neutrophil count (ANC) ≥1500 cells/mm³.
  8. Platelets ≥100000 cells/mm³.
  9. Haemoglobin ≥8 g/dL (Note: following a blood transfusion or another intervention if required).
  10. Adequate hepatic function: aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) ≤2.5 x upper limit of normal (ULN); or ≤3.5 x ULN in the case of concurrent disease with known etiology and for which a corrective treatment is possible.
  11. Adequate renal function: clearance >30 mL/min (MDRD).
  12. Patients having provided written informed consent prior to any study-related procedures.
  13. Patients affiliated to the social security scheme.
  14. Patients willing and able to comply with the scheduled visits, treatment plan, laboratory tests, and other study procedures indicated in the protocol.

Exclusion Criteria:

Patient must not be enrolled if he/she fulfils any of the following non-inclusion criteria:

  1. Patients with R1 resection and with orthotropic neo-bladder reconstruction as urinary diversion are not eligible.
  2. Patients with clinical or radiological evidence of metastases or N3 staged bladder cancer are not eligible.
  3. Prior invasive solid tumours or haematological malignancies unless disease free for a minimum of 3 years prior to randomisation except:

    • skin basal cell carcinoma,
    • in situ epithelioma of the cervix,
    • or prostate cancer: incidentally discovered during cystoprostatectomy and pelvic lymph node dissection and with a good prognosis (T stage <pT3b and/or Gleason <8 and pN- and/or post-operative prostate-specific antigen (PSA) <0.1 nanogram/mL),
  4. Prior pelvic radiotherapy.
  5. Patients with active inflammatory bowel disease.
  6. Patients who required surgical treatment for bowel obstruction before bladder cancer diagnosis or after cystectomy.
  7. Prior chemotherapy for other malignant diseases within the previous 5 years, except for neoadjuvant pre-cystectomy chemotherapy or adjuvant chemotherapy which are permitted.
  8. Patients with the following severe acute co-morbidity are not eligible:

    • Unstable angina or congestive heart failure that required hospitalization in the 6 months before randomisation.
    • Transmural myocardial infarction in the 6 months prior to randomisation.
    • Acute bacterial or fungal infection requiring intravenous antibiotics at randomisation.
    • Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of randomisation.
    • Severe hepatic disease: Child-Pugh Class B or C hepatic disease.
    • Known acquired immune deficiency syndrome (AIDS); the study treatment could impact blood count.
  9. Patients with any other disease or illness which requires hospitalization or is incompatible with the study treatment are not eligible.
  10. Patients unable to comply with study obligations for geographic, social, or physical reasons, or who are unable to understand the purpose and procedures of the study.
  11. Patients enrolled in another therapeutic study within 30 days prior of randomisation.
  12. Person deprived of their liberty or under protective custody or guardianship.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03333356


Contacts
Layout table for location contacts
Contact: Mallik ZIBOUCHE + 33 1 44 23 55 68 m-zibouche@unicancer.fr

Locations
Show Show 27 study locations
Sponsors and Collaborators
UNICANCER
Investigators
Layout table for investigator information
Principal Investigator: Paul SARGOS, MD Institut Bergonié
Principal Investigator: Stéphane LARRE, Prof CHU Robert Debré
Principal Investigator: Géraldine PIGNOT, MD Institut Paoli-Calmettes
Layout table for additonal information
Responsible Party: UNICANCER
ClinicalTrials.gov Identifier: NCT03333356    
Other Study ID Numbers: UC-0160/1617
2016-A01535-46 ( Registry Identifier: ANSM )
First Posted: November 6, 2017    Key Record Dates
Last Update Posted: September 28, 2021
Last Verified: September 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Bladder Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Urinary Bladder Diseases
Urologic Diseases